semaglutide heart failure fda Navigating the New Frontier: FDA's Approval of Wegovy for Cardiovascular Risk Reduction FDA approves semaglutide for major

Nitenberg A, Cosson E, Pham I

Lifestyle interventions are crucial for maintaining weight loss

G.et al (2018)

For the SELECT trial, the average weight loss results looked like this, around 10-11% of body weight: Source: Ryan, D.H., Lingvay, I., Deanfield, J

The recent meta-analyses indicated that in patients with high TMAO plasma level, the incidence of major adverse cardiovascular events was significantly higher compared with patients with low TMAO levels [67], and that all-cause mortality increased by 7.6% per each 10 mol/L increment of TMAO [68]

So by tackling obesity at its roots and boosting overall health, Semagalutid sets folks up for lasting success in losing weight